Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
UTILITY Therapeutics Joins Antimicrobials Working Group PR Newswire WASHINGTON, Feb. 17, 2021 WASHINGTON, Feb. 17, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the...
Shares in antibiotics developer Summit Therapeutics PLC were cancelled in London on Monday, a condition of its USD50 ...
AIM 24 February 2020 NOTICE 24/02/2020 NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM - XLON At the request of the Company the following securities have been cancelled from trading on AIM...
FTSE Russell 17 February 2020 Summit Therapeutics (UK): Constituent Deletion Changes in FTSE UK Index Series 17 February 2020 Subject to the expected cancellation of trading on AIM for Summit...
M Summit Therapeutics plc ("Summit Therapeutics" or the "Company") AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US, 11 February 2020 - Summit Therapeutics (AIM: SUMM...
M Summit Therapeutics plc ("Summit Therapeutics" or the "Company") Notification of Transaction of Persons Discharging Managerial Responsibilities Oxford, UK, and Cambridge...
Summit Therapeutics PLC on Thursday said it has achieved the first USD1 million milestone payment under its license a ...
M Summit Therapeutics plc ('Summit' or the 'Company') Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma -- Milestone Based on Achievement of Patient...
M Summit Therapeutics plc ('Summit' or the 'Company') Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 4 February...
M Summit Therapeutics plc ('Summit' or the 'Company') Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 27 January 2020 -- Summit Therapeutics plc (NASDAQ:...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
